Author

Jasmine M. Manouchehri

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Lynn M. MarchoiD· 2 shared Mathew Amprayil CherianiD· 2 shared Christopher Charles CossiD· 1 shared Jharna Datta· 1 shared Menglin XuiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Lynn M. MarchoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyFrontiers in OncologyPeer-reviewedMar 26, 2025

Potent Estrogen Receptor β Agonists with Inhibitory Activity In Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells

Lynn M. Marcho, Christopher Charles Coss, Menglin Xu…·Mathew Amprayil Cherian

The paper tests the in vivo efficacy of estrogen receptor β agonists combined with tamoxifen in endocrine-resistant breast cancer models, finding no tumor volume reduction despite in vitro success.

2 citations

mouseproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 15, 2023

Sulfatase 2 Inhibition Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy Through Augmentation of Extracellular ATP

Jasmine M. Manouchehri, Lynn M. Marcho, Mathew Amprayil Cherian

This study shows that sulfatase 2 inhibition enhances chemotherapy effectiveness in TNBC by increasing extracellular ATP release and reducing cancer-initiating cells.

DOI 10.1101/2023.09.15.557965

humanproteomics

𝕏 PostBluesky